 |
|
|
|
 |
|
|
| Article 1 to 9 out of 9 concerning Becton, Dickinson and Company
|
-
First European application filed for product using intradermal microinjection system BD Soluvia
(02/18/2008)
Novel influenza vaccine delivered using BD's innovative technology
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has submitted the first application in Europe to deliver a vaccine using BD Soluvia, a microinjection system developed by BD (Becton, Dickinson and Company). The submission for the first ...
-
BD Biosciences and StemCell Technologies Sign License Agreements with WARF
(06/19/2007)
Commercialization of Novel Culture Media and Surfaces for Human Embryonic Stem Cell Research
BD Biosciences, a segment of global medical technology company BD (Becton, Dickinson and Company), and StemCell Technologies, Inc. announced that they have each entered into a worldwide license agreement with the Wisconsin Alumni Research Foundation ...
-
BD Biosciences and Roche Collaborate on Study of Cell Signal Transduction through New Phosphorylation Site Antibody Targets
(02/28/2007)
BD Biosciences, a segment of BD (Becton, Dickinson and Company), and Roche announced a new collaboration to jointly identify and develop intracellular phosphorylation site antibodies that will improve their understanding of the pathways that carry ...
-
BD Commits $34 Million for Major Expansion in Québec
(02/12/2007)
30,200 square feet of new manufacturing space expected
BD (Becton, Dickinson and Company) announced the commitment of $34 million for a major expansion of its BD Diagnostics manufacturing operation in Québec, Canada. The investment shall allow BD to transfer out of its current leased space and establish ...
-
BD to Acquire TriPath Imaging, Inc.
(09/12/2006)
Advances BD's position in cancer diagnostics
BD (Becton, Dickinson and Company) announced that it has signed a definitive agreement to acquire the 93.5% of the outstanding shares of TriPath Imaging which BD does not currently own, for a cash purchase price of $9.25 per share, or approximately ...
-
Research Shows CD4 Testing Cost-Effective for HIV Patients in Areas Lacking Access to Second-Line ARV Treatments
(08/15/2006)
BD (Becton, Dickinson and Company) announced the release of a study by researchers from the Johns Hopkins Bloomberg School of Public Health at the XVI International AIDS Conference (AIDS 2006) that demonstrated conducting CD4 tests is a ...
-
BD Diagnostics Announces Agreement with BioReference Laboratories for BD Viper Robotic Instrumentation and Molecular Testing
(06/23/2006)
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced the signing of an agreement with BioReference Laboratories of Elmwood Park, NJ (BRLI) for BD to supply BRLI with instrumentation and reagents for testing and diagnosis of ...
-
VaxGen and BD to Jointly Evaluate Novel Dermal Injection Technology for Delivery of VaxGen's Anthrax Vaccine
(02/24/2006)
VaxGen, Inc. announced that they have entered into an agreement with BD (Becton, Dickinson and Company) on a program to evaluate the potential advantages of using BD's Micro Injection technology to deliver VaxGen's recombinant anthrax vaccine ...
-
BD Announces Agreement to Acquire GeneOhm Sciences, Inc.
(01/12/2006)
BD (Becton, Dickinson and Company) announced that it has signed an agreement to acquire GeneOhm Sciences, Inc. GeneOhm Sciences had 2005 revenues of approximately $5 million and provides BD with expanded entry into the emerging HAI (healthcare-associ...
Additional information
Becton, Dickinson and Company
Franklin Lakes, NJ, United States of America
Company
|
|
|
|
|
|
Top
